SCHEMBL4024341

SCHEMBL4024341

Cc1c(F)cccc1C1C(C(=O)c2ccccc2O)CN(CC(=O)N(C)C)CC1C(=O)c1ccccc1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
EED O75530 1/20 0.34
PIN1 Q13526 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
TERT O14746 2/20 0.32
DRD4 P21917 1/20 0.32
RIPK1 Q13546 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019242 1.00 KMT2A (0.34) KMT2AMEN1TAS1R3TAS1R1TAS1R2
SCHEMBL4024177 0.89 EED (0.36) KMT2AMEN1TAS1R3TAS1R1TAS1R2
SCHEMBL4022107 0.89 EED (0.36) KMT2AMEN1TAS1R3TAS1R1TAS1R2
SCHEMBL4020606 0.87 KDM2B (0.40) KMT2AMEN1PIN1KDM4EALDH1A1
SCHEMBL4027702 0.87 KDM2B (0.40) KMT2AMEN1PIN1KDM4EALDH1A1
SCHEMBL4751756 0.87 DRD4 (0.35) KMT2AMEN1TAS1R3TAS1R1TAS1R2
SCHEMBL4751758 0.87 DRD4 (0.35) KMT2AMEN1TAS1R3TAS1R1TAS1R2
SCHEMBL4019982 0.86 KMT2A (0.39) KMT2AMEN1EEDDRD4RIPK1
SCHEMBL4019987 0.86 KMT2A (0.39) KMT2AMEN1EEDDRD4RIPK1
SCHEMBL4027984 0.85 TAS1R3 (0.37) KMT2AMEN1TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KMT2A 2820/4885MEN1 77/4885TAS1R3 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.